Table of Contents
ISRN Neurology
Volume 2012, Article ID 451457, 5 pages
http://dx.doi.org/10.5402/2012/451457
Clinical Study

Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary

1MS Clinic, Department of Neurology, Centro Hospitalar de São João, 4200-319 Porto, Portugal
2Department of Neurology, Centro Hospitalar de Vila Nova Gaia/Espinho, 4434-502 Vila Nova de Gaia, Portugal
3Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal

Received 29 October 2012; Accepted 3 December 2012

Academic Editors: K. Dorovini-Zis, E. A. Joosten, T. Müller, Y. Ohyagi, Y. Sunada, and S. Weis

Copyright © 2012 Ana Teresa Carvalho and Maria José Sá. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Mendes and J. M. Sá, “Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works,” Arquivos de Neuro-Psiquiatria, vol. 69, no. 3, pp. 536–543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Sá, J. Guimarães, P. Abrea, A. Mendes, and E. B. Souto, “Etiopathogenesis, classical immunotherapy and innovative nanotherapeutics for inflammatory neurological disorders,” Current Nanoscience, vol. 7, no. 1, pp. 2–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Gauthier, B. I. Glanz, M. Mandel et al., “Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study,” Journal of the Neurological Sciences, vol. 284, no. 1-2, pp. 116–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H. P. Hartung, and R. Hohlfeld, “Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations,” Journal of Neurology, vol. 255, no. 10, pp. 1449–1463, 2008. View at Google Scholar
  5. C. Evans, J. Tam, E. Kingwell, J. Oger, and H. Tremlett, “Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study,” Clinical Therapeutics, vol. 34, no. 2, pp. 341–350, 2012. View at Google Scholar
  6. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Coppola, R. Lanzillo, C. Florio et al., “Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis,” European Journal of Neurology, vol. 13, no. 9, pp. 1014–1021, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Waubant, S. Vukusic, L. Gignoux et al., “Clinical characteristics of responders to interferon therapy for relapsing MS,” Neurology, vol. 61, no. 2, pp. 184–189, 2003. View at Google Scholar · View at Scopus
  9. V. Tomassini, A. Paolillo, P. Russo et al., “Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis,” Journal of Neurology, vol. 253, no. 3, pp. 287–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Pozzilli, L. Prosperini, E. Sbardella, L. De Giglio, E. Onesti, and V. Tomassini, “Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience,” Neurological Sciences, vol. 26, no. 4, pp. S174–S178, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. K. Daugherty, J. S. Butler, M. Mattingly, and M. Ryan, “Factors leading patients to discontinue multiple sclerosis therapies,” Journal of the American Pharmacists Association, vol. 45, no. 3, pp. 371–375, 2005. View at Google Scholar · View at Scopus
  12. A. Cucci, P. Barbero, M. Clerico et al., “Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose,” Journal of Neuroimmunology, vol. 226, no. 1-2, pp. 150–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker, “Multiple sclerosis,” New England Journal of Medicine, vol. 343, no. 13, pp. 938–952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. G. S. M. Ramsaransing and J. De Keyser, “Benign course in multiple sclerosis: a review,” Acta Neurologica Scandinavica, vol. 113, no. 6, pp. 359–369, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. G. Weinshenker, B. Bass, G. P. A. Rice et al., “The natural history of multiple sclerosis: a geographically based study—2. Predictive value of the early clinical course,” Brain, vol. 112, no. 6, pp. 1419–1428, 1989. View at Google Scholar · View at Scopus
  16. P. O'Connor, “Key issues in the diagnosis and treatment of multiple sclerosis: an overview,” Neurology, vol. 59, pp. 1–3, 2002. View at Google Scholar
  17. S. Castro, J. Guimarães, P. Carinha et al., “Adherence to immunomodulatory drugs in multiple sclerosis: evaluation of discontinuation reasons,” Sinapse, vol. 6, no. 1, pp. 36–40, 2006. View at Google Scholar · View at Scopus